logo Click here for the Chao Family Comprehensive Cancer Center Home Page Click here for the UC Irvine Home Page

Onco-Imaging and Biotechnology Program (OIB)

The broad goal of the OIB Program is to develop and assess quantitative systems and technologies that improve detection, clinical management, and quality of life for cancer patients.  Our main scientific themes are Cancer imaging and treatment using Biophotonics, MRI, Nuclear, X-Ray, and multi-Modality technologies; and Cancer detection and therapy using molecular, cellular, and material technologies.   Many of these technologies are custom-designed and fabricated within the Laser Microbeam and Medical Program (LAMMP) and the Laboratory for Fluorescence Dynamics (LFD), NIH P41 Biomedical Technology Centers in the Beckman Laser Institute and the Department of Biomedical Engineering.  These technologies include a broad range of non-linear optical microscopies, Optical Coherence Tomography, Opto- acoustic and elastographic imaging, Laser Speckle Imaging, Spatial Frequency Domain Imaging, and Diffuse Optical Spectroscopy and Imaging.  We also develop nano- and microfluidic technologies and integrated “lab on a chip” systems to advance cellular and molecular diagnostics for improved cancer detection and therapy. This includes new technologies and methods for engineering cellular systems such that their integration into devices allows visualization and testing of the complex dynamics between cells, vasculature and extracellular matrix. These in vitro engineered tissues are used to advance our understanding of the disease process and as a test bed to determine response to therapy.  Each of the OIB themes is used in translational research spanning from animal models to human subjects in various types of cancers, including breast, skin, and colon.  We also apply emerging imaging technologies in multi-center and cooperative group clinical trials in order to standardize and validate methods and endpoints for improved cancer detection and clinical management.

Hughes Christopher C. Hughes, Ph.D.,  co-Leader of the OIB, has a joint appointment in Biomedical Engineering and is on the Leadership Council for the Edwards Lifesciences Center for Advanced Cardiovascular Technology. Dr. Hughes has extensive experience in the field of vascular biology and the process of angiogenesis.
Bruce Tromberg, Ph.D. Bruce J. Tromberg, Ph.D.,  co-Leader of the OIB, is the Director of the Beckman Laser Institute and Medical Clinic (BLI) and the Laser Microbeam and Medical Program (LAMMP), an NCRR P41 Biomedical Technology Center.  Dr. Tromberg’s goal is to both lead and facilitate the development and application of novel multi-modality imaging and spectroscopy technologies, so they are successfully integrated and implemented in Cancer Center programs.